A Clinical Study of the Selective MAO-A-Inhibitor Moclobemide (Ro 11-1163): a Comparison of 2 Different Dosages with Particular Reference to Platelet MAO-Activity and Urinary MHPG-Excretion
- 1 April 1987
- journal article
- clinical trial
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 2 (2) , 165-171
- https://doi.org/10.1097/00004850-198704000-00011
Abstract
A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder. Two different doses of medication were given for 4 weeks. Effectiveness was measured by improvements in the Hamilton Rating Scale for Depression, a self-rating scale and clinical global impression. Platelet MAO-activity and urinary MHPG-excretion was also determined. Moclobemide proved to be a well-tolerated and effective antidepressant, with both groups showing improvement. Platelet MAO-activity was not markedly influenced by moclobemide, possibly because it selectively inhibits MAO-A. Urinary MHPG did not change significantly with treatment.Keywords
This publication has 0 references indexed in Scilit: